

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
16 December 2021 (16.12.2021)



(10) International Publication Number
WO 2021/252718 A1

(51) International Patent Classification:

A61K 31/437 (2006.01) A61K 45/06 (2006.01)
A61K 31/4706 (2006.01) A61P 37/02 (2006.01)
A61K 31/573 (2006.01)

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(21) International Application Number:

PCT/US2021/036740

(22) International Filing Date:

10 June 2021 (10.06.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

202011024586 11 June 2020 (11.06.2020) IN

Published:

- with international search report (Art. 21(3))

(71) Applicant: **BRISTOL-MYERS SQUIBB COMPANY**
[US/US]; Route 206 and Province Line Road, Princeton,
New Jersey 08543 (US).

(72) Inventors: **SCHIEVEN, Gary L.**; 519 Bergen
Street, Lawrenceville, New Jersey 08648 (US). **DUD-
HGAONKAR, Shailesh**; c/o Syngene International Limited,
Biocon Special Economic Zone, Biocon Park, Plot No.
2 & 3, Bommasandra Industrial Area IV Phase, Jigani Link
Road, Bommasandra, Bangalore Karnataka 560 099 (IN).

(74) Agent: **GREENBLATT, Gary D.** et al.; Bristol-Myers
Squibb Company, Route 206 and Province Line Road,
Princeton, New Jersey 08543 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: TLR7 INHIBITOR IN COMBINATION WITH PREDNISOLONE OR HYDROXYCHLOROQUINE FOR TREATING CUTANEOUS LUPUS ERYTHEMATOSUS

(57) Abstract: Disclosed is method of treating a patient having cutaneous lupus erythematosus, comprising administering to said patient a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective dose of a second agent selected from prednisolone and hydroxychloroquine or a pharmaceutically acceptable salt thereof.

WO 2021/252718 A1